Follow The Filings

IMMX Immix Biopharma Inc.

Health Care, filed as IMMIX BIOPHARMA INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 1 Owner
  • Max 2.2%
  • $24M
  • 1 new

In 2026 Q2 James Silverman opened a position in Immix Biopharma.

Who owns this now

Largest portfolio weights among holders, up to 2.2% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman New 2.2%

Who owns IMMX

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 2.2% New 2.2% 2,345,000 $24M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IMMX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMMX insider trades
  • $10K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Ilya M Rachman CEO
    Buy
    $4,976 746 shares at $6.67 +0.1% to stake
    Traded Dec 10, 2025 Filed Dec 10, 2025
    ↗
  2. Gabriel S Morris CFO
    Buy
    $5,067 770 shares at $6.58 +0.3% to stake
    Traded Dec 10, 2025 Filed Dec 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 stock grants and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-K/A Filing Doc
10-K Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$15.43M -$21.61M -$29.44M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $19.79M $20.2M $101.24M
Total non-current assets * $0.137M $2.75M $3.6M
Total assets $19.93M $22.95M $104.84M
Total current liabilities $3.72M $8.69M $10.11M
Total non-current liabilities * $0M $1.01M $0.934M
Total equity $16.41M $13.25M —

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$11.37M -$14.6M -$23.93M
Cash from investing -$0.052M -$1.18M -$7.21M
Cash from financing $15.46M $15.95M $107.39M
Net change in cash $4.07M $0.172M $76.25M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Q2 2026

Period archive